Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer support

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43876   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    861 result(s) found for: cancer support. Displaying page 1 of 44.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005576-26 Sponsor Protocol Number: 08-PIR-04 Start Date*: 2009-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable L...
    Medical condition: Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005578-12 Sponsor Protocol Number: 08-PIR-06 Start Date*: 2009-03-02
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanc...
    Medical condition: Patients with Metastatic or Locally Advanced Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000988-25 Sponsor Protocol Number: version4 Start Date*: 2012-04-27
    Sponsor Name:Gateshead Health NHS Trust Research & Development
    Full Title: To determine the feasibility of using Microbubble technology to detect sentinel nodes in vulvar cancer.
    Medical condition: Early stage vulvar cancer with no clinial or radiological evidence of lymph node metastases
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003731-37 Sponsor Protocol Number: CA209-907 Start Date*: 2017-10-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, single-arm Phase II Safety Study of Nivolumab in Subjects with Advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior syst...
    Medical condition: Advanced or metastatic non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-001005-26 Sponsor Protocol Number: GECP 05-01 Start Date*: 2005-09-07
    Sponsor Name:Spanish Lung Cancer Group
    Full Title: A single-arm phase II study of dose-dense gemcitabine and carboplatin as neoadyuvant chemotherapy, with pegfilgrastim support for subjects with operable stage IIIA NSCLC
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000486-29 Sponsor Protocol Number: GIM9 (NEO-ADIXERN) Start Date*: 2008-06-03
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer
    Medical condition: In ER-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005577-36 Sponsor Protocol Number: 08-PIR-05 Start Date*: 2009-02-19
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Who...
    Medical condition: Patients with Metastatic Breast Cancer Whose Disease has Failed Taxane-Based Treatment
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004093-40 Sponsor Protocol Number: 08-PIR-03 Start Date*: Information not available in EudraCT
    Sponsor Name:Nektar Therapeutics
    Full Title: A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, ...
    Medical condition: Refractory Solid Tumors (Colorectal Cancer) Tumores sólidos refractarios (Cáncer colorrectal)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer LLT
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) SK (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-003262-41 Sponsor Protocol Number: GO28509 Start Date*: 2013-05-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) AT (Completed) CZ (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003016-32 Sponsor Protocol Number: APHP180690 Start Date*: 2020-01-24
    Sponsor Name:Assistance Publique – Hôpitaux de Paris
    Full Title: Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutropenic patients with sepsis:A randomized 2 by 2 factorial design randomized pragm...
    Medical condition: neutropenic patients with sepsis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002667-53 Sponsor Protocol Number: 213409 Start Date*: 2021-08-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit...
    Medical condition: advanced ovarian, breast, or prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002829-28 Sponsor Protocol Number: B8011011 Start Date*: 2021-06-01
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)
    Medical condition: locally advanced or metastatic NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005076-26 Sponsor Protocol Number: SGNTV-001 Start Date*: 2019-04-16
    Sponsor Name:Seagen, Inc.
    Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
    Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033600 Pancreatic adenocarcinoma non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059326 Pancreatic carcinoma stage IV PT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059333 Pancreatic carcinoma stage IVA LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059335 Pancreatic carcinoma stage IVB LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061902 Pancreatic neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010023 Colorectal neoplasms malignant HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002018-37 Sponsor Protocol Number: BO27938 Start Date*: 2013-04-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BRE...
    Medical condition: HER2-positive primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) SE (Ongoing) AT (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) IE (Ongoing) ES (Ongoing) GR (Ongoing) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-000806-39 Sponsor Protocol Number: CECOG/BREAST.2.2.005 Start Date*: 2005-02-10
    Sponsor Name:CECOG
    Full Title: Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early B...
    Medical condition: Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10006199 PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005754-80 Sponsor Protocol Number: STING 2 Start Date*: 2007-10-15
    Sponsor Name:Karolinska University Hospital [...]
    1. Karolinska University Hospital
    2. Swedish Lung Cancer Group
    3.
    Full Title: Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study.
    Medical condition: Small Cell Lung Cancer (limited disease)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000509-29 Sponsor Protocol Number: BO25734/TDM4997g Start Date*: 2011-12-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of trastuzumab emtansine compared with treatment of physician’s choice in patients with HER2-positive metasta...
    Medical condition: HER2-Positive Metastatic Breast Cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) SK (Completed) BE (Completed) CZ (Completed) HU (Completed) NO (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005095-18 Sponsor Protocol Number: ICR-CTSU/2013/10041 Start Date*: 2014-09-19
    Sponsor Name:The Institute of Cancer Research
    Full Title: A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
    Medical condition: Low risk non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-002443-21 Sponsor Protocol Number: CO44195 Start Date*: 2023-03-01
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER
    Medical condition: Grade 1 Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014738 Endometrial cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002048-42 Sponsor Protocol Number: MO29406 Start Date*: 2015-01-29
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-l...
    Medical condition: Solid Tumours (Future parent protocols may include other solid tumors that are not included in this section)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) IT (Ongoing) FR (Ongoing) PL (Completed) PT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 10 08:49:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA